VOYAGER THERAPEUTICS, INC.
Last · —$2.01-0.14 (-6.51%)live · yahoo · 1s ago
Vol 1.19M ≈ 2.40M
MA10MA20MA50
Market cap$123.85M—
P/E · TTM—fwd — · eps —
Beta—vs S&P 500
Div yield—annual · TTM
52w range
——
Volume—session
Issuer
Legal nameVOYAGER THERAPEUTICS, INC.
HQUnited States (US)
ListingUS VYGR
ISINUS92915B1061
SectorHealthcare
IndustryBiotechnology & Medical Research
SIC2836
CurrencyUSD
Entity registrysec:0001640266
CIK0001640266
Websitewww.voyagertherapeutics.com
Employees141
AddressVoyager Therapeutics, Inc. 75 Hayden Avenue 02421, Lexington +857 259 5340
| Revenue | $34.4M |
|---|---|
| Operating income | $-56.7M |
| Net income | $-52.4M |
| Free cash flow | $-59.3M |
| Operating margin | -164.6% |
| Net margin | -152.2% |
| Return on equity | -33.9% |
| Period | TTM 2026-06-30 |
Loading chart…
OpenFilings analyst
Our analyst
10-K · 2026-03-09
From latest 10-K · 2026-03-09
- Sbc Revenue High
- Operating Cf Burn
- Net Margin Sharply Negative
- Cash Conversion Weak
- Cash Runway Low
- Accumulated Deficit High
- Rd Intensity High
Red flags
- Sbc Revenue High — SBC/Revenue 36.6%
- Operating Cf Burn — Negative operating cash flow
- Net Margin Sharply Negative — Net margin -296.5%
- Cash Conversion Weak — Cash conversion (CFO/Rev) -328.1%
- Cash Runway Low — Cash runway ~0.5 years
- Accumulated Deficit High — Accumulated deficit / equity 227%
- Rd Intensity High — R&D/Revenue 333.6%
Upcoming earnings
MON.9NOV
9:00 PM UTC+1
Period
Sep 2026
Est. EPS
−$0.42
Est. revenue
6.3M
Press & signals
- GlobeNewswire
Voyager Reports Second Quarter 2026 Financial and Operating Results
Documents
FormReporting forFiledFlags
Showing 5 of 90 filings